BPAKESO@EC2610B

CanSino Biologics' AK112 Beats Merck's Keytruda, Achieves Systemic Transformation in Two Years

Guo Jin Securities Predicts Kangke Biotech's 2026 Net Profit to Grow Significantly

CICC and China International Securities Maintain Buy Rating and Set Target Price for Kangao Biologics

Canbiopharm Revenue Increases 43.9% in 2025, IVO-3001 FDA Application Accepted

CanAngen's Revenue Grew by 43.9% to 3.056 Billion Yuan in 2025

AKESO released FY2025 9-month earnings on March 26 (BJT), actual revenue HKD 2.427 B, actual EPS HKD -1.0188

AKESO released FY2025 Q3 earnings on March 26, 2026 (BJT) with actual revenue of HKD 898.99 M and EPS of HKD -0.3259

Kangkang Biotech Inc. Revenue Reaches 3.056 Billion Yuan in 2025, Loss Widens to 1.141 Billion Yuan

AKESO released FY2025 earnings on March 26 During-Market (BJT), actual revenue HKD 3.34 B (forecast HKD 3.655 B), actual EPS HKD -1.3473 (forecast HKD -0.3407)

AKESO released FY2025 Q4 earnings on March 26 During-Market (BJT), actual revenue HKD 914.5 M, actual EPS HKD -0.3315

AKESO to release FY2025 earnings report on March 26 During-Market (BJT), forecast revenue HKD 3.726 B, EPS HKD -0.3479

CanAngen's AK150 Receives Clinical Trial Approval

Nomura Adjusts Kanghong Biotech Revenue Forecast and Target Price

CanSino and Inovio Partner to Evaluate Efficacy in Glioblastoma Treatment

NMPA Approves Kangkang Biotech's AK139 to Enter Phase II Clinical Trials for 7 Indications

Kangkang Biologics Grants JinChuan Pharmaceutical Exclusive Commercialization Rights to Enoximab

CanSino Biologics' PD-1/VEGF Bi-specific Antibody Ivolimab Receives FDA Acceptance

CanSinoBio Updates Contract Manufacturing Arrangement with CTTQ-Akeso

BofA Securities Initiates Coverage of CanSino Biologics with a Buy Rating

Summit Submits BLA for Ivonescimab to FDA

JOY SPREADER

DEEPEXI TECH

BUTONG GROUP

CHINA PARTYTIME

ALPHA PRO HLDGS

LUEN THAI

51WORLD

TRIO IND ELEC

TOMO HOLDINGS

HATCHER GROUP

LABU

SBIO

Akeso, Inc. presented updated data on cadonilimab combination therapy for advanced NSCLC at ELCC 2026. The Phase Ib/II study showed a median progression-free survival of 7.0 months and a disease control rate of 95.2%. The combination therapy demonstrated meaningful anti-tumor activity and a manageable safety profile, supporting its potential as a second-line treatment option for patients resistant to PD-(L) 1 inhibitors. Akeso continues to innovate in biopharmaceuticals, focusing on developing first-in-class therapies.

prnewswire

Proshares UltraShort Nasdaq Biotech

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

VanEck Biotech ETF

23:28 ETAkeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L) 1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026

09926

CICC analyst maintained a Buy rating on Akeso, Inc. yesterday and set a price target of HK$184.00.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In a report released on March 30, CMB International Securities also maintained a Buy rating on the stock with a HK$185.80 price target.

Tip Ranks

AKESO

CICC Remains a Buy on Akeso, Inc. (9926)

159316

512010

159992

588250

159102

512290

560600

516500

159837

159892

588860

588130

520690

Keymed Biosciences Inc. has spun off its autoimmune drug into a new company, Ouro Medicines, which is being sold to Gilead Sciences for up to $2.175 billion. Keymed will receive approximately $320 million from this deal, including upfront payments and milestone payments. This marks a significant achievement for Keymed, as it is the first complete NewCo cycle from a Chinese drugmaker. The drug, currently in clinical trials, targets autoimmune diseases and has received FDA Fast Track and Orphan Drug status. Keymed's revenues rose 67% in 2025, despite a slight increase in net loss.

benzinga_article

E Fund Hang Seng SCHK Innovative Drug ETF

E Fund CSI 300 Health Care ETF

Yinhua CSI Innovative Drugs Industry ETF

Penghua SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Guotai CSI Bio-medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Minsheng Royal CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ICBCCS SSE STAR Biology and Medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Gilead Sciences

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

China Southern Hang Seng Biotech ETF(QDII)

A Healthy Return: Drug Spin-off Nets Keymed Up To $320M

Akeso, Inc. presented health-related quality of life (HRQoL) data from the HARMONi-2 study at the 2026 European Lung Cancer Congress. The study compared ivonescimab, a PD-1/VEGF bispecific antibody, with pembrolizumab for first-line treatment of PD-L1-positive non-small cell lung cancer (NSCLC). Results showed ivonescimab significantly improved median progression-free survival (PFS) and HRQoL, with better control of lung cancer symptoms. The findings support ivonescimab as a new standard of care in first-line lung cancer treatment, highlighting its clinical value and safety profile.

VG Health

iShares US Pharma

iShares Global Healthcare

Merck

Health Care Select Sector SPDR

05:40 ETIvonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026

06869

02513

02600

02338

06809

02714

06690

02333

01171

YOFC(06869) rose 14.34%, with a trading turnover 6.7 Billion HKD, and a year-to-date rose 281%. KNOWLEDGE ATLAS(02513) rose 9.81%, with a trading turnover 1.3 Billion HKD, and a year-to-date rose 531.2%. MONTAGE TECH(06809) fell 6.88%, with a trading turnover 230.6 Million HKD, and a year-to-date rose 54.5%. MUYUAN(02714) fell 6.04%, with a trading turnover 289.6 Million HKD, and a year-to-date fell 0.3%.

Top Gainers & Losers

YOFC

KNOWLEDGE ATLAS

CHALCO

WEICHAI POWER

MONTAGE TECH

MUYUAN

HAIER SMARTHOME

GWMOTOR

YANKUANG ENERGY

Top 5 HK Stock Gainers/Losers (>100B) (3.30)

BABA

02068

00700

01024

09992

09618

00883

01810

On March 30, intraday sentiment in the Hong Kong stock market was weak, with the three major indices collectively pulling back. The Hang Seng TECH Index fell by 2.90%. The internet, retail, and jewelry sectors led the market decline, with Tencent Holdings and Alibaba both dropping over 3%, and MEITU plunging over 8%. Despite the market pressure, CHALIECO rose nearly 20% against the trend. Market turnover was concentrated in technology heavyweight stocks, reflecting that funds remained active in trading amidst the adjustment

- As of March 30, Hong Kong stocks faced pressure, with major indices retreating amidst weak market sentiment.  
- The Hang Seng Index fell by 1.92% to 24,473.42, while the Hang Seng Tech Index dropped 2.90%, indicating a lack of upward momentum.  
- Investors are closely monitoring export and retail data, with macroeconomic pressures impacting market revaluation based on economic recovery pace and policy signals.

Market Heartbeat

Alibaba

CHALIECO

TENCENT

KUAISHOU-W

MNSO

CTG DUTY-FREE

POP MART

CHOW TAI FOOK

CALB

JD-SW

BYD COMPANY

CNOOC

XIAOMI-W

MEITUAN

SMIC

Hang Seng TECH Index

CSOP HS TECH

MEITU

Hong Kong Stocks Intraday | Hong Kong Stocks Slide Intraday; Tech Index Drops 2.90%, CHALIECO Rises Against the Trend

UBS lowered the target price for AKESO to RMB 173.4 due to its performance in the second half of last year being below expectations. The company's revenue grew by 50% year-on-year to RMB 1.64 billion, but the net loss widened to RMB 543 million. It is expected that revenue will grow by 44% to RMB 3.1 billion in 2025, with the net loss expanding to RMB 1.1 billion. Based on this, UBS adjusted its revenue forecasts for 2026 and 2027 and raised its sales and R&D expense forecasts, maintaining a "Buy" rating

AASTOCKS

Bosera Hang Seng Health Care ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

UBS lowers AKESO's target price to 173.4 yuan, performance in the second half of last year was below expectations

Keymed Biosciences' Loss Deepens in 2025

marketscreener

KEYMED BIO-B

Keymed Biosciences' Loss Deepens in 2025

Akeso, Inc.reported its 2025 financial results, showcasing a record commercial sales revenue of RMB3,033.1 million, a 51.48% increase year-on-year. The company’s products are now included in China's National Reimbursement Drug List, enhancing market access. Key developments include the successful clinical validation of ivonescimab and cadonilimab, both leading bispecific antibodies in oncology. Akeso is advancing multiple Phase III trials and expanding its portfolio with next-generation therapies, positioning itself for significant growth in 2026.

23:54 ETAkeso Reports Full-Year 2025 Financial Results

589720

Akeso FY revenue RMB 3,056.3 million

Guotai SSE STAR Brand Name Drug ETF

China Universal 800 Health Care ETF

Akeso FY revenue RMB 3,056.3 million

01772

00857

09980

00100

GANFENGLITHIUM(01772) rose 3.74%, with a trading turnover 1.4 Billion HKD, and a year-to-date rose 30.9%. CNOOC(00883) rose 2.53%, with a trading turnover 4.5 Billion HKD, and a year-to-date rose 37.2%. KUAISHOU-W(01024) fell 14.04%, with a trading turnover 9.1 Billion HKD, and a year-to-date fell 28.7%. POP MART(09992) fell 10.46%, with a trading turnover 15.4 Billion HKD, and a year-to-date fell 19.7%.

- The Hang Seng Index fell by 1.89% and has decreased by 3% year-to-date.  
- The Hang Seng Tech Index dropped 3.28%, with a year-to-date decline of 13.7%.  
- Notably, Ganfeng Lithium and CNOOC showed gains of 3.74% and 2.53% respectively, while Kuaishou and Pop Mart experienced significant losses of 14.04% and 10.46%.

GANFENGLITHIUM

PETROCHINA

EASTROC

MINIMAX-W

Top 5 HK Stock Gainers/Losers (>100B) (3.26)

03858

02228

On March 26th at noon, the three major indices of the Hong Kong stock market collectively adjusted, with the Hang Seng Index falling below the 25,000 mark, and the Hang Seng TECH Index experiencing the largest decline. Sector performance was mixed, with individual stocks in life sciences tools and services showing divergent trends, and Jiaxin International Resources plummeting significantly. Popular stocks like Kuaishou and Pop Mart led the market decline, while Xiaomi Group and CNOOC performed strongly, with overall market trading sentiment remaining cautious

- As of noon on March 26, Hong Kong’s three major indices experienced a collective decline, with cautious trading and weak sentiment noted.  
- The Hang Seng Index dropped by 1.37% to 24,988.04, while the Hang Seng Technology Index fell by 2.15% to 4,817.13, both retreating from their March 25 highs.  
- Notable movements included China National Offshore Oil (up 2.39%) and XiaoMi (up 1.54%), while Kuaishou and Alibaba saw significant declines.

JIAXIN INTL RES

XTALPI

Hang Seng Index

Hong Kong Stock Midday Review | Hang Seng Index falls 2.15% leading the decline, CNOOC and Xiaomi rise against the trend

The Hang Seng Index opened higher, refreshing its nearly four-year high; Tencent's performance exceeded expectations, receiving collective bullish calls from major banks; Chip stocks strengthened on the logic of domestic substitution, with SMIC leading the gains; Ping An's stake increase in China Taiping H-shares ignited the insurance sector; Cryptocurrency concept stocks surged as Bitcoin hit a new high; In the pharmaceutical sector, Jingtai Holdings reported its first profit, rising over 11%, while East Buy saw a sudden 12% increase.

Tencent

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Ping An Insurance

PING AN

PING AN-R

Ping An Ins HK SDR2to1

Ping An

SMIC HK SDR 5to1

CPIC

CHINA TAIPING

SUNSHINE INS

Life and Health Insurance

REMEGEN

RemeGen

Hot Trades in Hong Kong Stocks (8.14) | Hang Seng Index Hits Four-Year High at Opening, Morgan Stanley Says Foreign Capital Accelerated Inflows into Chinese Stock Market in July

BPAKESO@EC2610B(28184.HK)

BPAKESO@EC2610B Stock Performance Chart

23:28 ETAkeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L) 1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026

CICC Remains a Buy on Akeso, Inc. (9926)

A Healthy Return: Drug Spin-off Nets Keymed Up To $320M

05:40 ETIvonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026

Top 5 HK Stock Gainers/Losers (>100B) (3.30)